Biomea Fusion: reports Phase 1 results for BMF-650

What happened

• Biomea Fusion, Inc. reported on Oct 14, 2026 that it hosted a conference call and live webcast to discuss topline data from its ongoing Phase 1 GLP-131 clinical trial of BMF-650. The company also issued a press release on Oct 13, 2026 announcing Phase 1 results for BMF-650 and made a slide presentation available to accompany the call.

Key details

• The call and webcast discussed topline data for the Phase 1 GLP-131 clinical trial of BMF-650.
• The press release was issued on Oct 13, 2026 and announced Phase 1 results for BMF-650.
• The Form 8-K filed on Oct 14, 2026 reported Item 7.01 (Regulation FD disclosure) and Item 8.01 (other events).

Why it may matter

• Item 7.01 covers Regulation FD disclosure, which in this filing relates to the company hosting a conference call, webcast and providing a slide presentation about trial topline data. Item 8.01 covers other events, which in this filing is the Oct 13, 2026 press release announcing Phase 1 results for BMF-650. This filing does not show why an insider traded or why the company acted.